Characterization of the Release and Biological Significance of Cell-free DNA from Breast Cancer Cell Lines

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Jun 3

PMID 28574818

Citations 51

Authors

Wei Wang

Peng Kong

Ge Ma

Li Li

Jin Zhu

Tiansong Xia

Hui Xie

Wenbin Zhou

Shui Wang

Affiliations

Soon will be listed here.

Abstract

In breast cancer, cell-free DNA (cfDNA) has been proven to be a diagnostic and prognostic biomarker. However, there have been few studies on the origin and biological significance of cfDNA. In this study, we assessed the release pattern of cfDNA from breast cancer cell lines under different culture conditions and investigated the biological significance of cfDNA. The cfDNA concentration increased rapidly (6 h) after passage, decreased gradually, and was then maintained at a relatively stable level after 24 h. In addition, the cfDNA concentration did not correlate with the amount of apoptotic and necrotic cells. Interestingly, if more cells were in the G1 phase, more cfDNA was detected (p < 0.01) and the cfDNA concentration correlated positively with the percent of cells in the G1 phase (p < 0.05). We observed that cells could release cfDNA actively, but not exclusively, via exosomes. Furthermore, we showed that cfDNA could stimulate hormone receptor-positive breast cancer cell proliferation by activating the TLR9-NF-κB-cyclin D1 pathway. In conclusion, cfDNA is released from breast cancer mainly by active secretion, and cfDNA could stimulate proliferation of breast cancer cells.

Citing Articles

The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases.

Aydin S, Ozdemir S, Adiguzel A J Mol Neurosci. 2025; 75(1):34.

PMID: 40080233 PMC: 11906534. DOI: 10.1007/s12031-025-02317-8.

An appropriate DNA input for bisulfite conversion reveals LINE-1 and Alu hypermethylation in tissues and circulating cell-free DNA from cancers.

Tran T, Pham T, Nguyen T, Hien Do T, Luu P, Nguyen U PLoS One. 2025; 19(12):e0316394.

PMID: 39775734 PMC: 11684646. DOI: 10.1371/journal.pone.0316394.

Cargo exchange between human and bacterial extracellular vesicles in gestational tissues: a new paradigm in communication and immune development.

Amabebe E, Kumar A, Tatiparthy M, Kumar Kammala A, Taylor B, Menon R Extracell Vesicles Circ Nucl Acids. 2024; 5(2):297-328.

PMID: 39698538 PMC: 11648491. DOI: 10.20517/evcna.2024.21.

Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study.

Boeken T, Pellerin O, Bourreau C, Palle J, Gallois C, Zaanan A Radiol Med. 2024; 129(10):1530-1542.

PMID: 39183242 DOI: 10.1007/s11547-024-01865-0.

An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release.

Davidson B, Miranda A, Reed S, Bergman R, Kemp J, Reddy A Commun Biol. 2024; 7(1):441.

PMID: 38600351 PMC: 11006667. DOI: 10.1038/s42003-024-06129-1.

References

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts R, Pearson A, Tarazona N . Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7(313):313ra182. PMC: 4998737. DOI: 10.1126/scitranslmed.aac7551. View

Lowry M, Gallagher W, ODriscoll L . The Role of Exosomes in Breast Cancer. Clin Chem. 2015; 61(12):1457-65. DOI: 10.1373/clinchem.2015.240028. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

Peters D, Pretorius P . Origin, translocation and destination of extracellular occurring DNA--a new paradigm in genetic behaviour. Clin Chim Acta. 2011; 412(11-12):806-11. DOI: 10.1016/j.cca.2011.01.026. View

Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y . Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep. 2014; 4:4057. PMC: 3925966. DOI: 10.1038/srep04057. View

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View

Lamphier M, Sirois C, Verma A, Golenbock D, Latz E . TLR9 and the recognition of self and non-self nucleic acids. Ann N Y Acad Sci. 2006; 1082:31-43. DOI: 10.1196/annals.1348.005. View

Frasor J, Weaver A, Pradhan M, Dai Y, Miller L, Lin C . Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res. 2009; 69(23):8918-25. PMC: 2996265. DOI: 10.1158/0008-5472.CAN-09-2608. View

10.

Baumgarten S, Frasor J . Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 2012; 26(3):360-71. PMC: 3286192. DOI: 10.1210/me.2011-1302. View

11.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C . The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 2014; 16(4):421. PMC: 4303230. DOI: 10.1186/s13058-014-0421-y. View

12.

Volik S, Alcaide M, Morin R, Collins C . Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies. Mol Cancer Res. 2016; 14(10):898-908. DOI: 10.1158/1541-7786.MCR-16-0044. View

13.

Tuomela J, Sandholm J, Kaakinen M, Patel A, Kauppila J, Ilvesaro J . DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells. Breast Cancer Res Treat. 2013; 142(3):477-87. PMC: 4238912. DOI: 10.1007/s10549-013-2762-0. View

14.

Lacroix M, Leclercq G . Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004; 83(3):249-89. DOI: 10.1023/B:BREA.0000014042.54925.cc. View

15.

Atianand M, Fitzgerald K . Molecular basis of DNA recognition in the immune system. J Immunol. 2013; 190(5):1911-8. PMC: 3660856. DOI: 10.4049/jimmunol.1203162. View

16.

Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S . Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014; 146(1):163-74. DOI: 10.1007/s10549-014-2946-2. View

17.

Gravina S, Sedivy J, Vijg J . The dark side of circulating nucleic acids. Aging Cell. 2016; 15(3):398-9. PMC: 4854914. DOI: 10.1111/acel.12454. View

18.

Gahan P, Stroun M . The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct. 2010; 28(7):529-38. DOI: 10.1002/cbf.1690. View

19.

Sandholm J, Selander K . Toll-like receptor 9 in breast cancer. Front Immunol. 2014; 5:330. PMC: 4105583. DOI: 10.3389/fimmu.2014.00330. View

20.

Thakur B, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B . Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014; 24(6):766-9. PMC: 4042169. DOI: 10.1038/cr.2014.44. View